Crossmark

Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation

Crossref DOI link: https://doi.org/10.1186/s12916-018-1110-y

Published Online: 2018-08-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Samuel, Didier http://orcid.org/0000-0001-9481-3616
Coilly, Audrey
License Information

Text and Data Mining valid from 2018-08-01
More Information

Article History

Received: 15 August 2017

Accepted: 25 June 2018

First Online: 1 August 2018

Ethics approval and consent to participate

: Not available.

: Not available.

: Didier Samuel declares consultancy for and payments from Novartis, Merck Sharp and Dohme, Biotest, Gilead Sciences, Abbvie and Intercept. Audrey Coilly consultancy for and payment for lectures from Novartis, Astellas, Janssen, Bristol-Myers-Squibb (BMS), Merck Sharp & Dohme, Gilead and Roche. However, this has had no influence on the content of the manuscript. Dr. Coilly and Professor Samuel wrote this paper in total independence and this manuscript reflects their personal opinion.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.